RET gene fusion
1 drugsPredictive biomarker for patient selection in 4 indications
1
Approved Drugs
4
Indications
1
Companies
RET gene fusion is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 4 indications including Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Thyroid Cancer. Explore the targeted therapies, indications, testing methods, and companies developing RET gene fusion drugs below.
Search RET gene fusion Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting RET gene fusion
| Drug | Company | Therapeutic Area |
|---|---|---|
| RETEVMO | Eli Lilly | Oncology |